Cover Image
市場調查報告書

PharmaPoint:潰瘍性大腸炎(UC) - EU5個國家的醫藥品的預測與市場分析

PharmaPoint: Ulcerative Colitis - 5EU Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 300567
出版日期 內容資訊 英文 173 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:潰瘍性大腸炎(UC) - EU5個國家的醫藥品的預測與市場分析 PharmaPoint: Ulcerative Colitis - 5EU Drug Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 173 Pages
簡介

2012年到2022年潰瘍性大腸炎(UC)治療藥市場,預測將在Johnson & Johnson(Simponi)、武田藥品工業(Entyvio)的加入下大幅成長,主要國家(美國、歐盟五國、日本、加拿大)預計接受生技藥品治療的患者數將會增加。此外由於UC的暢銷藥物(Remicade,Humira)在美國專利到期,生技仿製藥的發售有影響市場的可能性。

本報告提供EU5個國家的UC治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 症狀
    • QOL

第4章 疾病的管理

  • 診斷和治療概要
    • 診斷
    • 治療的指南主要的處方藥
    • 臨床診療
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
    • Remicade(infliximab)
    • Humira(adalimumab)
    • Simponi(golimumab)
    • Apriso(mesalamine)
    • Asacol HD(mesalamine)
    • Lialda(mesalamine)
    • Pentasa(mesalamine)
    • Colazal(balsazide disodium)
    • Uceris(budesonide)
    • 其他
  • 生技仿製藥

第6章 機會及未滿足需求

  • 概要
  • 未滿足需求
  • 未滿足需求的差距分析
  • 疾病的嚴重程度與以大腸癌生物標靶為基礎的預後工具
  • 難治性的預測因素

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
    • Entyvio(vedolizumab)
    • Xeljanz(tofacitinib)
    • Kappaproct(DIMS 0150)

第8章 市場預測

  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表

目錄
Product Code: GDHC219CFR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

France emerged as the highest-grossing UC market in 2012 in GlobalData's forecast. Germany follows a reference pricing approach for drug reimbursement. Under this system, drugs that are considered to be therapeutically equivalent are clustered together and a reference price is set based on the least expensive drug in the cluster. In 2012, the base year of the forecast period, GlobalData estimated that the size of the UC market in Italy was $138m. This sales figure positions Italy as the lowest-grossing market in the 5EU, with approximately 10% of the total 5EU market value. Austerity measures within Spain led GlobalData to predict that biosimilar uptake will be strong, particularly within the moderate to severe UC patient group, Despite drug pricing pressures and the current global financial crisis, the UK is predicted to be the second-highest growing market for UC in GlobalData's forecast.

Scope

  • Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Ulcerative Colitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. France
  • 4.3. Germany
  • 4.4. Italy
  • 4.5. Spain
  • 4.6. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles. Major Brands
    • 5.3.1. Remicade (infliximab)
    • 5.3.2. Humira (adalimumab)
    • 5.3.3. Simponi (golimumab)
    • 5.3.4. Apriso (mesalamine)
    • 5.3.5. Asacol HD (mesalamine)
    • 5.3.6. Lialda (mesalamine)
    • 5.3.7. Pentasa (mesalamine)
    • 5.3.8. Colazal (balsazide disodium)
    • 5.3.9. Uceris (budesonide)
    • 5.3.10. Other Drug Classes Used in the Treatment of UC
  • 5.4. Biosimilars
    • 5.4.1. Introduction
    • 5.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 5.4.3. Biosimilars in the Immunology Community
    • 5.4.4. By the Numbers: Biosimilars in Development
    • 5.4.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Curative Therapy for Severe UC Patients
    • 6.2.2. Diagnostic Markers for Disease Severity
    • 6.2.3. Personalized Therapy
    • 6.2.4. A Replacement for Steroids
    • 6.2.5. Novel Oral Drug Formulations
    • 6.2.6. Preventative Medicine for Lowering the Associated Colorectal Cancer Risk
    • 6.2.7. Improved Management of Infectious Adverse Events
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools
  • 6.5. Predictors of Medically-Refractory Disease

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Entyvio (vedolizumab)
    • 7.2.2. Xeljanz (tofacitinib)
    • 7.2.3. Kappaproct (DIMS 0150)

8. Market Outlook

  • 8.1. France
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers
  • 8.2. Germany
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Italy
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Spain
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. United Kingdom
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed UC Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. Primary Research. Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Truelove and Witts UC Severity Index
  • Table 4: UCDAI
  • Table 5: Treatment Guidelines for UC Used in the 10MM
  • Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 7: UC Management Country Profile - France
  • Table 8: UC Management Country Profile - Germany
  • Table 9: UC Management Country Profile - Italy
  • Table 10: UC Management Country Profile - Spain
  • Table 11: UC Management Country Profile - UK
  • Table 12: Leading Treatments for UC, 2014
  • Table 13: Product Profile - Remicade
  • Table 14: Remicade SWOT Analysis, 2014
  • Table 15: Product Profile - Humira
  • Table 16: Humira Efficacy in the ULTRA 2 Trial
  • Table 17: Product Efficacy Comparison - Humira vs. Remicade
  • Table 18: Humira SWOT Analysis, 2014
  • Table 19: Product Profile - Simponi
  • Table 20: Simponi SWOT Analysis, 2014
  • Table 21: Product Profile - Apriso
  • Table 22: Apriso SWOT Analysis, 2014
  • Table 23: Product Profile - Asacol HD
  • Table 24: Asacol HD SWOT Analysis, 2014
  • Table 25: Product Profile - Lialda
  • Table 26: Lialda SWOT Analysis, 2014
  • Table 27: Product Profile - Pentasa
  • Table 28: Pentasa SWOT Analysis, 2014
  • Table 29: Product Profile - Colazal
  • Table 30: Colazal SWOT Analysis, 2014
  • Table 31: Product Profile - Uceris
  • Table 32: Uceris SWOT Analysis, 2014
  • Table 33: Summary of Other Immunomodulators for UC, 2013
  • Table 34: Biosimilars Pipeline, 2013
  • Table 35: Overall Unmet Needs - Current Level of Attainment
  • Table 36: Corticosteroid Long-Term Side Effects
  • Table 37: Clinical Unmet Needs in UC - Gap Analysis, 2013
  • Table 38: Prognostic Markers in UC
  • Table 39: UC - Pre-Registration and Phase III Pipeline, 2014
  • Table 40: Comparison of Therapeutic Classes in Development for UC, 2014
  • Table 41: Product Profile - Entyvio
  • Table 42: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC
  • Table 43: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC
  • Table 44: Most Common Adverse Events with Vedolizumab in the GEMINI I Study
  • Table 45: Entyvio SWOT Analysis, 2014
  • Table 46: Product Profile - Xeljanz
  • Table 47: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC
  • Table 48: Most Common Adverse Events in the Phase IIa Trial of Xeljanz
  • Table 49: Xeljanz SWOT Analysis, 2014
  • Table 50: Product Profile - Kappaproct
  • Table 51: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC
  • Table 52: Kappaproct SWOT Analysis, 2014
  • Table 53: Sales Forecasts ($m) for UC in France, 2012-2022
  • Table 54: Key Events Impacting Sales for UC in France, 2012-2022
  • Table 55: UC Market in France - Drivers and Barriers, 2012-2022
  • Table 56: Sales Forecasts ($m) for UC in Germany, 2012-2022
  • Table 57: Key Events Impacting Sales for UC in Germany, 2012-2022
  • Table 58: UC Market in Germany - Drivers and Barriers, 2012-2022
  • Table 59: Sales Forecasts ($) for UC in Italy, 2012-2022
  • Table 60: Key Events Impacting Sales for UC in Italy, 2012-2022
  • Table 61: UC Market in Italy - Drivers and Barriers, 2012-2022
  • Table 62: Sales Forecasts ($m) for UC in Spain, 2012-2022
  • Table 63: Key Events Impacting Sales for UC in Spain, 2012-2022
  • Table 64: UC Market in Spain - Drivers and Barriers, 2012-2022
  • Table 65: Sales Forecasts ($m) for UC in the UK, 2012-2022
  • Table 66: Key Events Impacting Sales for UC in the UK, 2012-2022
  • Table 67: UC Market in the UK - Drivers and Barriers, 2012-2022
  • Table 68: Key launches for Ulcerative Colitis , 2012-2022
  • Table 69: Key Patent Expiries
  • Table 70: Annual Cost of Therapy for 5-ASAs ($)
  • Table 71: Physicians Surveyed, 5EU

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: UC Disease Management Flowchart
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022
  • Figure 4: Sales for UC in France by Drug Class, 2012-2022
  • Figure 5: Sales for UC in Germany by Drug Class, 2012-2022
  • Figure 6: Sales for UC in Italy by Drug Class, 2012-2022
  • Figure 7: Sales for UC in Spain by Drug Class, 2012-2022
  • Figure 8: Sales for UC in the UK by Drug Class, 2012-2022
Back to Top